Diligence memo · auto-generated · as of July 2, 2026

Perkinelmer Inc

Perkinelmer Inc has raised $2.2B over 1 round; too few niche peers to rank its valuation yet.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Perkinelmer Inc operates in Biotech, based in WALTHAM. PerkinElmer | Science with Purpose

Sub-sector tags: ai/ml, biotech, healthtech, pharma.

Capital & rounds (filed)filed

Perkinelmer Inc has raised $2.2B in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).

Largest single filing: $2.2B on 2021-09-17.

Most recent recorded round closed around 2021-09-17.

Valuation (modeled)modeled

Provath models Perkinelmer Inc at approximately $65.2B (range $13.7B–$105.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Last raise 4.8 yr ago; this sector typically re-raises about every 11 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 100% of Biotech peers (233 compared).

Modeled value ranks above 100% of those peers.

Peoplefiled

14 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.